- Home
- CXM vs IBRX Comparison
CXM vs IBRX Comparison
Compare CXM & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXM
- IBRX
- Stock Information
- Founded
- CXM 2009
- IBRX 2014
- Country
- CXM United States
- IBRX United States
- Employees
- CXM N/A
- IBRX N/A
- Industry
- CXM Computer Software: Prepackaged Software
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CXM Technology
- IBRX Health Care
- Exchange
- CXM Nasdaq
- IBRX Nasdaq
- Market Cap
- CXM 2.2B
- IBRX 2.4B
- IPO Year
- CXM 2021
- IBRX N/A
- Fundamental
- Price
- CXM $8.43
- IBRX $2.66
- Analyst Decision
- CXM Hold
- IBRX Strong Buy
- Analyst Count
- CXM 14
- IBRX 5
- Target Price
- CXM $9.79
- IBRX $11.40
- AVG Volume (30 Days)
- CXM 1.0M
- IBRX 11.3M
- Earning Date
- CXM 06-04-2025
- IBRX 05-12-2025
- Dividend Yield
- CXM N/A
- IBRX N/A
- EPS Growth
- CXM 144.44
- IBRX N/A
- EPS
- CXM 0.44
- IBRX N/A
- Revenue
- CXM $796,394,000.00
- IBRX $31,222,000.00
- Revenue This Year
- CXM $4.24
- IBRX $579.01
- Revenue Next Year
- CXM $5.47
- IBRX $173.61
- P/E Ratio
- CXM $19.18
- IBRX N/A
- Revenue Growth
- CXM 8.74
- IBRX 10238.41
- 52 Week Low
- CXM $6.75
- IBRX $1.83
- 52 Week High
- CXM $11.79
- IBRX $7.63
- Technical
- Relative Strength Index (RSI)
- CXM 58.80
- IBRX 53.05
- Support Level
- CXM $7.97
- IBRX $2.43
- Resistance Level
- CXM $8.55
- IBRX $2.79
- Average True Range (ATR)
- CXM 0.18
- IBRX 0.23
- MACD
- CXM 0.02
- IBRX 0.02
- Stochastic Oscillator
- CXM 74.80
- IBRX 53.80
About CXM Sprinklr Inc.
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.